AI Insight
The SYNCHRONIZE-CVOT trial evaluated cardiovascular safety of survodutide, a dual glucagon receptor-GLP-1 receptor agonist, in adults with obesity at elevated cardiovascular risk. Results showed that survodutide treatment was not associated with increased risk of major adverse cardiovascular events, including cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, coronary revascularization, or heart failure events, compared to placebo. This phase 3, double-blind, randomized controlled trial demonstrates cardiovascular safety of this novel obesity treatment in a high-risk population.
Why it matters
This trial provides critical safety data for clinicians considering survodutide as a treatment option for patients with obesity who have existing cardiovascular disease, chronic kidney disease, or elevated cardiovascular risk. The findings support that this dual-agonist therapy can be used without increasing cardiovascular harm in vulnerable patient populations who need effective obesity management.
Understand the Science
In participants with obesity with established cardiovascular disease or chronic kidney disease or at increased risk of cardiovascular disease, survodutide was not associated with increased risk for the primary composite endpoint of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure event compared with placebo. This cardiovascular safety trial provides clinicians with reassuring data that treatment with survodutide, a novel glucagon receptor–GLP-1 receptor dual agonist, is not associated with increased cardiovascular risk.